Repurposing a US Cell Therapy Facility for Flexibility and EU Compliance
Cover: The explosive growth of advanced therapy medicinal products (ATMPs), particularly cellular therapeutics, has driven steady investment in facilities capable of manufacturing these therapeutics at scale. Meanwhile, the industry is collectively moving to adapt to European Union Annex 1 standards, which places a more stringent emphasis on contamination control.
Pharma Facilities, Composable Tools, and Validation 4.0
Feature: The pharmaceutical industry stands at the precipice of a revolution as emerging digital technologies provide new opportunities to boost productivity through continuous process improvements. The Pharma 4.0™ framework, an adaptation of the broader Industry 4.0 movement, aims to transform how drugs are produced and delivered.
Gene Editing and Facility Retrofits for Crispr and Beyond
Feature: With the approval of the first gene edited therapeutic in 2023, production of gene edited therapies is accelerating, introducing tough decisions for manufacturing development. Gene editing therapy production is complex, o en involving multimodality manufacturing operations in one facility to produce a single therapeutic. This article considers whether retrofitting an aging monoclonal antibody (mAb) facility for the manufacture of a gene editing therapy could be a solution.
Acceptable Discoloration Levels on Pharmaceutical Weld Beads
Technical: Welds used in biopharmaceutical manufacturing must meet critical criteria to maintain a defined level of purity and bioburden control. One highly debated area of concern is the level of discoloration allowable on the product contact surfaces in the welded condition and secondary finishing methods. This article addresses the studies commissioned by the American Society for Mechanical Engineers (ASME) to determine the allowed discoloration in the heat affected zone (HAZ) and weld bead.
Artificial Intelligence Governance in GxP Environments
Technical: companies, providing support from drug discovery through manufacturing. The nature of AI and concerns of bias, privacy, transparency, and security in a regulated industry necessitate a governance framework to ensure concerns are controlled using “guardrails.” These guardrails ensure the quality, privacy, and security of data used in AI applications. This article provides a recommended approach to implementing guardrails through several policies and procedures and discusses AI governance, which defines data ownership, consent, and access policies and procedures.